Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label ustekinumab in pediatric moderate to severe plaque psoriasis
2016-000121-40Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ustekinumab in plaque psoriasis and psoriasis, sponsored by Janssen Pharmaceutical. Primary endpoint: PGA 0/1 response at Week 12. Started Mar 2016; status: completed.
02
Drugs
ustekinumab
03
Conditions
plaque psoriasispsoriasis
Beyond the preview
Go deeper on 2016-000121-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000121-40.